This combination medication is commonly used to provide supportive relief during acute episodes of respiratory illness, such as the common cold or symptoms of upper respiratory allergies. It is generally applied in contexts where additional symptomatic support is needed for multiple, co-occurring distressing manifestations.

This dual-action medication is commonly used across conditions presenting with acute episodes of discomfort and is applied in addressing the combined burden of chest congestion, nasal/sinus congestion, and a phlegmy cough. The expectorant component helps address the buildup of excessive mucus in the chest, while the decongestant helps relieve symptoms related to physical discomfort from nasal tissue swelling by addressing symptoms in both the chest and nasal passages.

“It provides supportive relief that helps ease the overall symptom burden by addressing symptoms in both the chest and nasal passages simultaneously.”

It supports the patient by assisting with the thinning of thick secretions and is relevant for easing symptom clusters that interfere with daily comfort, such as a stuffy nose and sinus pressure, by supporting the temporary easing of restricted airflow.

---

Quick Fact: Symptomatic Support for Congestion
Primary Symptom Domains	Chest Congestion, Nasal Congestion, Excessive Mucus
Key Focus of Symptomatic Support	Relevant for supporting mucus clearance and easing restricted nasal airflow
Typical Use Context	Acute episodes of the common cold and seasonal allergies

Regulatory References

1. information published by the National Library of Medicine available via DailyMed

Who Can and Cannot Use Guaifenesin and Pseudoephedrine

This section summarizes the official population eligibility rules for guaifenesin and pseudoephedrine combination products, as documented by regulatory authorities.

Populations with Absolute Contraindications

The medicine must not be used in certain populations, primarily due to the pseudoephedrine component. Contraindications include patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or those who have discontinued MAOI therapy within the past 14 days. Use is also strictly forbidden in patients diagnosed with Severe Hypertension or Severe Coronary Artery Disease (CAD). Additionally, the product is contraindicated in patients with Narrow Angle Glaucoma or Urinary Retention.

Age and Condition Restrictions

Age restrictions apply: most adult-strength, extended-release formulations are contraindicated in children under 12 years of age. Regulatory guidance generally advises against giving any OTC cough and cold medicine to children under four years of age.

Use requires caution in patients with specific chronic health conditions, including Diabetes Mellitus, Hyperthyroidism, or existing Glaucoma. Caution is also advised for those with impaired renal function or hepatic impairment. Individuals who are pregnant or breastfeeding are instructed to consult a health professional before use.

Interaction Map: Interactions with other medicines and products — official regulatory information for Eksofed (Guaifenesin and Pseudoephedrine)

Interaction scope Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Ergot Derivatives, Sympathomimetic Agents, Tricyclic Antidepressants (TCAs), SNRIs, and Urinary pH Modifiers. Specific interacting medicines (if explicitly listed): Linezolid, Iobenguane I 123/131, Acetazolamide, and Ammonium Chloride. Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (PD) synergism resulting in additive sympathomimetic effects; Pharmacokinetic (PK) alteration via urinary pH modification. Timing-based interaction rules (if applicable): A mandatory separation of at least 14 days is required between discontinuing MAOIs and initiating this medicine. Population-specific interaction notes (if applicable): Clearance is significantly reduced in patients with severe renal impairment, increasing the potential for drug accumulation. Interaction-related restrictions: Strictly contraindicated combinations must not be co-administered.

Interaction classifications (high-level) Interaction severity classification (as defined in official documents): Contraindicated (MAOIs, Ergot Derivatives), Increased Risk of Adverse Effects (TCAs, Caffeine), Altered Exposure (Urinary pH Modifiers). Regulatory basis (EMA / FDA / etc.): Information is based on official government prescribing documents. Interaction-context constraints (as defined in official documents): Risk of hypertensive crisis, risk of enhanced pressor/tachycardic effects, and risk of diminished therapeutic/diagnostic effect (with Iobenguane).

Resulting interaction structure Official interaction statements:

• Co-administration is formally contraindicated with MAOIs, including Linezolid, due to the documented risk of hypertensive crisis.
• Urinary alkalinizing agents (e.g., Acetazolamide) may increase the serum concentration of Pseudoephedrine by reducing its elimination rate.
• Combination with Tricyclic Antidepressants or high amounts of Caffeine may result in enhanced sympathetic effects on blood pressure and heart rate.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define this product's interaction structure through the Pseudoephedrine component, which introduces major Pharmacodynamic (PD) restrictions involving agents that amplify sympathetic activity. This PD risk dictates the contraindicated classifications and establishes the mandatory 14-day timing separation rule. A secondary structure involves Pharmacokinetic (PK) alteration where substances changing urinary pH formally increase or decrease the drug's exposure.

Alpha-Adrenergic Receptor-Mediated Vascular Constriction

This mechanism relies on pseudoephedrine acting as an agonist on alpha-adrenergic receptors in the respiratory microvasculature. This signaling initiates vasoconstriction and reduces blood flow, decreasing the fluid leakage that causes tissue edema and ultimately achieves the patency of the upper airway. This mechanism operates by targeting vascular tone and capillary pressure, contrasting with anti-inflammatory mechanisms that primarily address mediators like prostaglandins or leukotrienes.

The Gastro-Pulmonary Vagal Reflex Activation

The expectorant action of guaifenesin is driven by its ability to stimulate sensory receptors in the gastric mucosa, triggering the gastro-pulmonary vagal reflex. This reflex leads to increased output from bronchial glands, resulting in a higher volume of watery secretions that modulate mucus rheology to be less viscous. This pathway differs from mechanisms involving direct molecular binding at the target organ, relying instead on a systemic neuro-humoral pathway to enhance secretion.

Complementary Mechanisms Affecting Vascular and Secretory Systems

The product engages two distinct and non-competitive mechanistic domains: one controls vascular swelling (reduction of edema) and the other modifies secretion viscosity (fluid volume). The physiological result is the simultaneous achievement of upper airway patency and lower airway clearance. The simultaneous action of these mechanisms results in physiological adjustments across both upper and lower respiratory tracts.

The administration of the Guaifenesin and Pseudoephedrine combination product is restricted to the oral route, available in immediate-release (IR) and extended-release (ER) forms, such as tablets and oral solutions. Official instructions define precise dosing intervals and quantity limits to ensure proper use, emphasizing adherence to the product's design.

---

Official Dosing and Administration

Dosage Form	Adult/Pediatric (12 Years and Older) Dosing	Maximum Daily Dose (Active Ingredients)
Immediate-Release (IR)	One dose every 4 hours (e.g., 400 mg Guaifenesin/40 mg Pseudoephedrine)	2400 mg Guaifenesin / 240 mg Pseudoephedrine
Extended-Release (ER)	One or two tablets every 12 hours (e.g., 1200 mg/120 mg or 600 mg/60 mg)	2400 mg Guaifenesin / 240 mg Pseudoephedrine

---

Preparation and Usage Constraints

The product can be administered without regard for the timing of meals. All tablet forms, particularly the extended-release design, must be swallowed whole with a full glass of water and must not be crushed, chewed, or broken to maintain the controlled release of the components.

Use is intended for a short-term course; official labeling warns against administration if symptoms do not improve within 7 days. The extended-release formulation is officially directed not to be used in children under 12 years of age. If a dose is missed, individuals should return to the regular schedule and not take a double dose. Adherence to these protocols governs the standardized usage of this combination medication.

Evidence Base for Acute Respiratory Symptoms

The core research for the guaifenesin/pseudoephedrine combination has been applied in studies examining patient-reported experiences during short-term episodes of illness. The clinical evidence primarily comes from short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated in settings comparing it against a placebo or an active comparison group. This research focuses on conditions characterized by fluctuating or episodic manifestations, such as the common cold and Acute Upper Respiratory Tract Infections (URTIs).

Studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort related to cough, chest congestion, nasal stuffiness, and sinus pressure. Researchers specifically examined temporary changes in these outcomes describing episodic or acute changes when comparing the combination to placebo. The overall body of evidence contributes to understanding symptom patterns over the duration of a typical cold.

Study Design and Clinical Endpoints Examined

To assess outcomes related to systemic or functional imbalance, studies explored designs where participants were observed in controlled settings. These included double-blind studies, where neither the patient nor the doctor knew if the combination product or an inactive placebo was studied for symptom patterns. The main outcomes related to physical discomfort research examined included composite symptom scores and individual measures such as the severity of nasal congestion and the intensity of a phlegmy cough.

Evidence in Specific Populations and Research Gaps

The majority of the evidence is derived from settings with varying symptom burdens involving Adults. Dedicated research exploring the use of the combination was studied for certain pediatric groups, such as children aged 6 to 11 years. However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes or efficacy specific to older adults who may have multiple underlying health conditions.

The follow-up durations were limited for efficacy trials, generally lasting seven days or less. Long-term effects are not fully established, and there are few data available for assessing how the medicine was evaluated in people with underlying chronic respiratory conditions. Evidence highlights what is known — and what is still uncertain — about the full scope of the medicine's use.

Key Studies & References

1. A Phase 1 Bioequivalence Study of an Extended-Release Combination of Pseudoephedrine and Guaifenesin (Example Regulatory Submission/Clinical Trial Record)

Common questions about Eksofed (+guaifenesin) (FAQ)

Q: Is it safe for me to use this drug if I have a history of heart disease, like high blood pressure (hypertension)?

Official product information states that this medicine is contraindicated (should not be used) in patients with severe or uncontrolled hypertension (high blood pressure) and severe coronary artery disease. Use requires caution in individuals with other heart or vascular conditions, or a history of heart issues. Information regarding the full health history should be reviewed with a healthcare professional before beginning use.

Q: What should I do with the unused portion of my medicine when the treatment is over?

Regulatory disposal guidelines specify that unused or expired medication should not be flushed down the toilet or poured into a drain. Disposal methods should follow established guidelines, such as utilizing a drug take-back program. If a take-back program is unavailable, official sources recommend securing the product in household trash after mixing it with an undesirable substance, and ensuring it is safely kept out of reach of children and pets.

Q: What is the mechanism of action for the expectorant component, guaifenesin, and how does it help with chest congestion?

Guaifenesin works as an expectorant by stimulating the gastro-pulmonary vagal reflex, a specific nervous system pathway. This action increases the volume and reduces the viscosity (thickness) of secretions in the respiratory tract. This mechanism helps to thin and loosen mucus, resulting in a more productive cough for clearing chest congestion.

Q: Can older adults (65 years and older) use this combination drug safely?

Official information indicates that older adults may be more susceptible to the adverse effects of the pseudoephedrine component, such as a fast heartbeat or central nervous system effects like dizziness and nervousness. Use in this population is generally advised with caution. Reviewing the product with a healthcare provider is recommended for individuals 65 and older.

Q: How do I know if my symptoms are severe enough to require a doctor's visit while taking this drug?

Regulatory documents advise patients to contact a healthcare provider if their respiratory symptoms do not improve within 7 days of using this medicine, or if they worsen. Furthermore, medical attention should be sought if symptoms are accompanied by a new fever, rash, or persistent headache.

Q: What are the key differences between a decongestant and an expectorant?

These two drug classes serve different functions in the body. A decongestant (like pseudoephedrine) works by narrowing blood vessels, which reduces swelling in the nasal passages to relieve a stuffy nose. An expectorant (like guaifenesin) works to thin and loosen mucus in the chest, making it easier to cough up and clear the airways.

How to Store and Dispose of Eksofed (+guaifenesin)

Storage and disposal requirements for guaifenesin and pseudoephedrine are documented in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Environmental	Liquid forms must be protected from freezing.
Container	Keep the product in its original carton and do not use if tamper-evident seals are compromised.

Protection and Disposal

All medicine must be kept out of reach of children. Unused or expired medication should not be flushed down the toilet or poured into a drain. Disposal should follow established guidelines, such as utilizing a drug take-back program or securing the product in household trash mixed with an undesirable substance.